Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 1,944 | 933 | 58,980 | 44,356 | 14,981 |
| Gross Profit | 1,944 | 933 | 58,980 | 44,356 | 14,981 |
| Operating Expenses | 53,223 | 63,498 | 87,572 | 108,775 | 101,372 |
| Operating Income | -51,279 | -62,565 | -28,592 | -64,419 | -86,391 |
| Other Income | 6,109 | 9,810 | 9,711 | 8,056 | 2,828 |
| Pre-tax Income | -45,170 | -52,755 | -18,881 | -56,363 | -83,563 |
| Net Income Continuous | -45,170 | -52,755 | -18,881 | -56,363 | -83,563 |
| Net Income | $-45,170 | $-52,755 | $-18,881 | $-56,363 | $-83,563 |
| EPS Basic Total Ops | -0.46 | -0.54 | -0.19 | -0.58 | -0.86 |
| EPS Basic Continuous Ops | -0.46 | -0.54 | -0.19 | -0.58 | -0.86 |
| EPS Diluted Total Ops | -0.46 | -0.54 | -0.19 | -0.58 | -0.86 |
| EPS Diluted Continuous Ops | -0.46 | -0.54 | -0.19 | -0.58 | -0.86 |
| EBITDA(a) | $-49,796 | $-61,039 | $-19,500 | $-59,692 | $-82,824 |